Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

556 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial.
Harrison CN, Mesa R, Talpaz M, Al-Ali HK, Xicoy B, Passamonti F, Palandri F, Benevolo G, Vannucchi AM, Mediavilla C, Iurlo A, Kim I, Rose S, Brown P, Hernandez C, Wang J, Kiladjian JJ. Harrison CN, et al. Among authors: mesa r. Lancet Haematol. 2024 Oct;11(10):e729-e740. doi: 10.1016/S2352-3026(24)00212-6. Epub 2024 Sep 9. Lancet Haematol. 2024. PMID: 39265613 Clinical Trial.
Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib.
Mesa R, Verstovsek S, Platzbecker U, Gupta V, Lavie D, Giraldo P, Recher C, Kiladjian JJ, Oh ST, Gerds AT, Devos T, Passamonti F, Vannucchi AM, Egyed M, Lech-Maranda E, Pluta A, Nilsson L, Shimoda K, McLornan D, Kawashima J, Klencke B, Huang M, Strouse B, Harrison C. Mesa R, et al. Haematologica. 2024 Feb 1;109(2):676-681. doi: 10.3324/haematol.2023.283106. Haematologica. 2024. PMID: 37259556 Free PMC article. No abstract available.
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study.
Gerds AT, Verstovsek S, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Oh S, Klencke BJ, Yu J, Donahue R, Kawashima J, Mesa R. Gerds AT, et al. Among authors: mesa r. Lancet Haematol. 2023 Sep;10(9):e735-e746. doi: 10.1016/S2352-3026(23)00174-6. Epub 2023 Jul 27. Lancet Haematol. 2023. PMID: 37517413 Clinical Trial.
Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis.
Oh ST, Mesa RA, Harrison CN, Bose P, Gerds AT, Gupta V, Scott BL, Kiladjian JJ, Lucchesi A, Kong T, Buckley SA, Tyavanagimatt S, Harder BG, Roman-Torres K, Smith J, Craig AR, Mascarenhas J, Verstovsek S. Oh ST, et al. Among authors: mesa ra. Blood Adv. 2023 Oct 10;7(19):5835-5842. doi: 10.1182/bloodadvances.2023010151. Blood Adv. 2023. PMID: 37552106 Free PMC article.
Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials.
Kiladjian JJ, Vannucchi AM, Gerds AT, Gupta V, Verstovsek S, Egyed M, Platzbecker U, Mayer J, Grosicki S, Illés Á, Woźny T, Oh ST, McLornan D, Kirgner I, Yoon SS, Harrison CN, Klencke B, Huang M, Kawashima J, Mesa R. Kiladjian JJ, et al. Among authors: mesa r. Hemasphere. 2023 Oct 27;7(11):e963. doi: 10.1097/HS9.0000000000000963. eCollection 2023 Nov. Hemasphere. 2023. PMID: 37908862 Free PMC article.
A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: stage 2 of a phase II trial.
Verstovsek S, Talpaz M, Wadleigh M, Isidori A, Te Boekhorst P, Savona MR, Bose P, Pozdnyakova O, Mesa R, El-Galaly TC, O'Sullivan J, Gamel K, Higgins B, Katakam S, Todorov B, Trunzer K, Harrison CN. Verstovsek S, et al. Among authors: mesa r. Haematologica. 2024 Jun 1;109(6):1977-1983. doi: 10.3324/haematol.2023.284410. Haematologica. 2024. PMID: 38268448 Free PMC article. Clinical Trial. No abstract available.
Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis.
Oh ST, Verstovsek S, Gupta V, Platzbecker U, Devos T, Kiladjian JJ, McLornan DP, Perkins A, Fox ML, McMullin MF, Mead AJ, Egyed M, Mayer J, Sacha T, Kawashima J, Huang M, Strouse B, Mesa R. Oh ST, et al. Among authors: mesa r. EJHaem. 2024 Feb 5;5(1):105-116. doi: 10.1002/jha2.854. eCollection 2024 Feb. EJHaem. 2024. PMID: 38406514 Free PMC article.
Erratum to: Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia.
Verstovsek S, Mesa R, Talpaz M, Kiladjian JJ, Harrison CN, Oh ST, Vannucchi AM, Rampal R, Scott BL, Buckley SA, Craig AR, Roman-Torres K, Mascarenhas JO. Verstovsek S, et al. Among authors: mesa r. Haematologica. 2024 Apr 1;109(4):3010. doi: 10.3324/haematol.2023.284815. Haematologica. 2024. PMID: 38562076 Free PMC article. No abstract available.
Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial.
Gupta V, Yacoub A, Mesa RA, Harrison CN, Vannucchi AM, Kiladjian JJ, Deeg HJ, Fazal S, Foltz L, Mattison RJ, Miller CB, Parameswaran V, Brown P, Hernandez C, Wang J, Talpaz M. Gupta V, et al. Leuk Lymphoma. 2024 Sep;65(9):1314-1324. doi: 10.1080/10428194.2024.2346733. Epub 2024 Jun 5. Leuk Lymphoma. 2024. PMID: 38838026 Clinical Trial.
556 results